Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences and Abiomed . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.
Currently, Integra LifeSciences has a Zacks Rank of #2 (Buy), while Abiomed has a Zacks Rank of #4 (Sell). The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that IART has an improving earnings outlook. But this is only part of the picture for value investors.
Value investors are also interested in a number of tried-and-true valuation metrics that help show when a company is undervalued at its current share price levels.
Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.
IART currently has a forward P/E ratio of 15.10, while ABMD has a forward P/E of 33.25. We also note that IART has a PEG ratio of 1.27. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. ABMD currently has a PEG ratio of 1.58.
Another notable valuation metric for IART is its P/B ratio of 2.76. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, ABMD has a P/B of 6.73.
These are just a few of the metrics contributing to IART's Value grade of B and ABMD's Value grade of D.
IART is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that IART is likely the superior value option right now.
对医疗器械股票感兴趣的投资者可能熟悉 Integra LifeSciences 和 Abomed 。但这两只股票中哪一只对价值投资者更具吸引力？我们需要更仔细地观察才能发现。
找到高价值股票的最好方法是在我们的风格评分系统的价值类别中对一个强大的 Zacks 评级。ZackRank 是一种经验证的策略，它针对的是盈利预测修正趋势为正的公司，而我们的 Style Score 则根据具体的特点对公司进行评级。
目前， Integra LifeSciences 的 Zacks 排名为#2（购买），而 Abomed 的 Zacks 排名为#4（销售）。Zacks Rank 看好近期对收益预期做出积极修正的股票，因此投资者应该放心， IART 的盈利前景将会改善。但这只是价值投资者的一部分。
IART 目前的远期市盈率为15.10倍， ABMD 的远期市盈率为33.25倍。我们还注意到， IART 的 PEG 比率为1.27。这个流行的数字与广泛使用的市盈率类似，但 PEG 比率也考虑了公司预期的每股收益增长率。ABMD 目前的 PEG 比率为1.58。
IART 的另一个显著的估值指标是其 P / B 比率为2.76。市盈率是用来比较股票的市场价值与其账面价值，即总资产减去总负债。比较而言， ABMD 的 P / B 为6.73。
这些仅仅是导致 IART 的 B 值等级和 ABMD 的 D 值等级的一些指标。
IART 目前的盈利前景正在改善，这使得它在 Zacks Rank 模型中表现突出。并且，基于上述估值指标，我们认为 IART 现在可能是更好的价值选择。